Fluvastatin SR from Actavis first to market in UK, Holland

Actavis Group, the international generic pharmaceuticals company, today announced the launch of Fluvastatin SR in the UK and the Netherlands. Actavis was first to market in both countries.

Fluvastatin SR extended release tablets from Actavis are the generic equivalent of Novartis’ Luvinsta® SR / Lescol® XL and are available in 80mg tablets in both markets. Fluvastatin SR is used to treat high cholesterol levels in the blood.

Fluvastatin SR tablets are manufactured by Actavis Malta and developed by Actavis’ R&D in Iceland.

This launch was possible after Actavis won a court case in January 2009 in the UK, whereby Novartis’ formulation patent for Fluvastatin SR, which prevented launch of the product until 2017, was revoked. The formulation patent has also been revoked in the Netherlands.

Actavis Group
Hjordis Arnadottir
Director – External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com

About Actavis Group
Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,000 employees. For more information about Actavis, please visit our website: www.actavis.com

Any statements contained in this press release that refer to Actavis’ estimated or anticipated future results or future activities are forward-looking statements which reflect the Company’s current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.

This press release was brought to you by Actavis